RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 SOR as Adjuvant Therapy after Resection for Pancreatic Cancer Does Not Improve DFS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 36
SP 21
OP 21
DO 10.1177/155989771436017
UL http://mdc.sagepub.com/content/14/36/21.abstract
AB Even after successful surgery intended as curative, up to 90% of patients with pancreatic cancer suffer a relapse. Adding sorafenib to gemcitabine as adjuvant therapy for patients after R1 resection for pancreatic cancer does not improve disease-free survival or overall survival compared with GEM alone. This article presents results from the phase 2b CONKO-006 study.